XML 52 R26.htm IDEA: XBRL DOCUMENT v3.5.0.2
License and Collaboration Agreements - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended
Oct. 25, 2016
Dec. 31, 2015
Jan. 31, 2015
Jan. 31, 2014
Jun. 30, 2011
Sep. 30, 2016
Sep. 30, 2015
Mar. 31, 2013
Jun. 30, 2016
Collaborative Agreements And Contracts [Line Items]                  
Collaborative research and development revenue           $ 34,000 $ 180,000    
Deferred revenue, less current portion           $ 5,585,000     $ 5,585,000
Percentage of outstanding share capital owned by Pfizer           5.40%      
Royalty income           $ 243,000 286,000    
Accounts receivable           462,000     488,000
Pfizer Collaboration Agreement [Member]                  
Collaborative Agreements And Contracts [Line Items]                  
Collaborative research and development revenue           0 0    
Upfront cash payment received under collaboration agreement         $ 2,300,000        
License option upfront payment upon exercise           10,000,000      
Estimated selling price of the deliverables for revenue recognition           6,700,000      
Deferred revenue, less current portion           $ 5,600,000     5,600,000
Pfizer Collaboration Agreement [Member] | Subsequent Event [Member]                  
Collaborative Agreements And Contracts [Line Items]                  
Option period to acquire license 60 days                
OncoSil Medical UK Limited [Member]                  
Collaborative Agreements And Contracts [Line Items]                  
Percentage of non-royalty consideration received from sublicense           20.00%      
Collaborative research and development revenue           $ 0 0    
License agreement commencement date           2012-12      
Receipt of upfront license fee               $ 100,000  
Royalty percentage earned from sales of product           8.00%      
Payment of annual license maintenance fee   $ 100,000 $ 100,000 $ 100,000          
Deferred revenue           $ 0      
Feasibility Study Agreement [Member]                  
Collaborative Agreements And Contracts [Line Items]                  
Collaborative research and development revenue           8,000,000 8,000,000    
Bausch and Lomb [Member]                  
Collaborative Agreements And Contracts [Line Items]                  
Royalty income           243,000 286,000    
Accounts receivable           $ 259,000     288,000
Alimera [Member]                  
Collaborative Agreements And Contracts [Line Items]                  
Percentage of company's share of net profits           20.00%      
Pre-profitability net losses percentage           20.00%      
Maximum percentage offset of current period net profits against previously incurred and unapplied pre-profitability quarterly net losses           4.00%      
Percentage of net profit share after offset of previously incurred and unapplied pre-profitability net losses           16.00%      
Percentage of royalties received from sublicense           20.00%      
Percentage of non-royalty consideration received from sublicense           33.00%      
Collaborative research and development revenue           $ 20,000 163,000    
Non-royalty consideration received from sublicense             $ 157,000    
Deferred revenue           $ 136,000     $ 136,000